COVID-19 and comorbidities of hepatic diseases in a global perspective
Open Access
- 7 April 2021
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (13), 1296-1310
- https://doi.org/10.3748/wjg.v27.i13.1296
Abstract
The worldwide outbreak of coronavirus disease 2019 (COVID-19) has challenged the priorities of healthcare system in terms of different clinical management and infection transmission, particularly those related to hepatic-disease comorbidities. Epidemiological data evidenced that COVID-19 patients with altered liver function because of hepatitis infection and cholestasis have an adverse prognosis and experience worse health outcomes. COVID-19-associated liver injury is correlated with various liver diseases following a severe acute respiratory syndrome-coronavirus type 2 (SARS-CoV-2) infection that can progress during the treatment of COVID-19 patients with or without pre-existing liver disease. SARS-CoV-2 can induce liver injury in a number of ways including direct cytopathic effect of the virus on cholangiocytes/hepatocytes, immune-mediated damage, hypoxia, and sepsis. Indeed, immediate cytopathogenic effects of SARS-CoV-2 via its potential target, the angiotensin-converting enzyme-2 receptor, which is highly expressed in hepatocytes and cholangiocytes, renders the liver as an extra-respiratory organ with increased susceptibility to pathological outcomes. But, underlying COVID-19-linked liver disease pathogenesis with abnormal liver function tests (LFTs) is incompletely understood. Hence, we collated COVID-19-associated liver injuries with increased LFTs at the nexus of pre-existing liver diseases and COVID-19, and defining a plausible pathophysiological triad of COVID-19, hepatocellular damage, and liver disease. This review summarizes recent findings of the exacerbating role of COVID-19 in pre-existing liver disease and vice versa as well as international guidelines of clinical care, management, and treatment recommendations for COVID-19 patients with liver disease.Keywords
This publication has 88 references indexed in Scilit:
- Hepatocellular CarcinomaThe New England Journal of Medicine, 2019
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinomaJournal of Hepatology, 2018
- EASL Clinical Practice Guidelines: Management of alcohol-related liver diseaseJournal of Hepatology, 2018
- Genomic Profiling and Metabolic Homeostasis in Primary Liver CancersTrends in Molecular Medicine, 2018
- Chronic liver injury alters driver mutation profiles in hepatocellular carcinoma in miceJournal of Hepatology, 2018
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesJournal of Hepatology, 2015
- ACE2 – From the renin–angiotensin system to gut microbiota and malnutritionMicrobes and Infection, 2013
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- A Major Outbreak of Severe Acute Respiratory Syndrome in Hong KongThe New England Journal of Medicine, 2003
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003